Observes safety of Entresto in children with chronic heart failure
Studies safety of Entresto tablets or granules in children with chronic heart failure.
Plain-language title generated from the registry record
Registry title: Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Key facts
- Where
- Akita, Bunkyo Ku, Fuchū, Fukuoka, Hamamatsu, Hidaka, Kawasaki, Kumamoto, Kurume, Nagasaki, Ōbu, Okayama, Ōmura, Ōta-ku, Saitama, Sapporo, Setagaya-ku, Shinagawa Ku, Shinjuku Ku, Toyama, Toyoake, Tsu, Tsukuba, and Yokohama, JapanSee the 24 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 1 and 17 years old?
Source: NCT06659393, who can take part
Where in Japan
- AkitaAkita, JapanTaking people
- Bunkyo KuBunkyo Ku, JapanTaking people
- FuchūFuchū, JapanTaking people
- FukuokaFukuoka, JapanNo longer taking part
- HamamatsuHamamatsu, JapanTaking people
- HidakaHidaka, JapanTaking people
- KawasakiKawasaki, JapanTaking people
- KumamotoKumamoto, JapanNo longer taking part
- KurumeKurume, JapanTaking people
- NagasakiNagasaki, JapanTaking people
- ŌbuŌbu, JapanTaking people
- OkayamaOkayama, JapanTaking people
- ŌmuraŌmura, JapanTaking people
- Ōta-kuŌta-ku, JapanTaking people
- SaitamaSaitama, JapanTaking people
- SapporoSapporo, JapanTaking people
- Setagaya-kuSetagaya-ku, JapanTaking people
- Shinagawa KuShinagawa Ku, JapanTaking people
- Shinjuku KuShinjuku Ku, JapanTaking people
- ToyamaToyama, JapanTaking people
- ToyoakeToyoake, JapanTaking people
- TsuTsu, JapanTaking people
- TsukubaTsukuba, JapanTaking people
- YokohamaYokohama, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06659393
- Record updated
- 13 April 2026
- Original description
This is multicenter, single-arm, non-interventional, centrally enrolled specified drug-use survey to investigate the safety of Entresto Tablets or Entresto Granules for Pediatric in pediatric patients with chronic heart failure in actual clinical settings for up to 52 weeks after administration.Read full original descriptionShow less
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure, CLCZ696F1401)
This is multicenter, single-arm, non-interventional, centrally enrolled specified drug-use survey to investigate the safety of Entresto Tablets or Entresto Granules for Pediatric in pediatric patients with chronic heart failure in actual clinical settings for up to 52 weeks after administration.
Inclusion: Written informed consent by a legally acceptable representative must be obtained before the start of treatment with Entresto; Patients who received Entresto for the first time under the indication of chronic heart failure; Pediatric patients aged 1 to < 18 years old at the start of treatment with Entresto.
Exclusion: Patients who have received drugs containing the same ingredient as Entresto (including investigational products and drugs for post-marketing clinical study); Patients for whom Entresto is contraindicated according to the package insert; Patients with a history of hypersensitivity to any ingredients of Entresto; Patients currently under treatment with angiotensin-converting enzyme inhibitors or within 36 hours of discontinuation of treatment with angiotensin-converting enzyme inhibitors (alacepril, imidapril hydrochloride, enalapril maleate, captopril, quinapril hydrochloride, cilazapril hydrate, temocapril hydrochloride, delapril hydrochloride, trandolapril, benazepril hydrochloride, perindopril erbumine, lisinopril hydrate); Patients with a history of angioedema (including angioedema due to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors, hereditary angioedema, acquired angioedema, and idiopathic angioedema etc.); Patients with diabetes mellitus under treatment with aliskiren fumarate (excluding patients with markedly poorly controlled blood pressure despite other antihypertensive therapies); Patients with severe hepatic impairment (Child-Pugh class C); Pregnant women or women who may be pregnant.